Cargando…

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization

Bcl-2 family of proteins consists of both pro-apoptotic and anti-apoptotic members that control cellular apoptosis. They predominantly reside in the mitochondria and control the release of apoptotic factors from the mitochondria to the cytosol by regulating its membrane potential and opening the PT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saxena, Nishant, Katiyar, Shashank P., Liu, Ye, Grover, Abhinav, Gao, Ran, Sundar, Durai, Kaul, Sunil C., Wadhwa, Renu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2013
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797589/ https://www.ncbi.nlm.nih.gov/pubmed/24050266 http://dx.doi.org/10.1042/BSR20130034

Ejemplares similares

Targeting Mortalin by Embelin Causes Activation of Tumor Suppressor p53 and Deactivation of Metastatic Signaling in Human Breast Cancer Cells
por: Nigam, Nupur, et al.
Publicado: (2015)

Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1
por: Meidinna, Hazna Noor, et al.
Publicado: (2022)

Bcl-xL in neuroprotection and plasticity
por: Jonas, Elizabeth A., et al.
Publicado: (2014)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

Nutritional Regulators of Bcl-xL in the Brain
por: Park, Han-A, et al.
Publicado: (2018)

Mimicking Cdk2 phosphorylation of Bcl-xL at Ser73 results in caspase activation and Bcl-xL cleavage
por: Seng, NS, et al.
Publicado: (2016)

Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers
por: Putri, Jayarani F., et al.
Publicado: (2019)

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020)

Bcl-xL as a Modulator of Senescence and Aging
por: Mas-Bargues, Cristina, et al.
Publicado: (2021)

Bcl-xL: A Focus on Melanoma Pathobiology
por: Lucianò, Anna Maria, et al.
Publicado: (2021)

Involvement of Bcl-xL in Neuronal Function and Development
por: Bas, Julie, et al.
Publicado: (2021)

The Role of Bcl-xL Protein in Viral Infections
por: Wyżewski, Zbigniew, et al.
Publicado: (2021)

Roles and Regulation of BCL-xL in Hematological Malignancies
por: Morales-Martínez, Mario, et al.
Publicado: (2022)

Advances in Bcl-xL Research 2.0
por: Kervadec, Joann, et al.
Publicado: (2023)

Identification and Characterization of Mortaparib(Plus)—A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Type p53-Dependent and -Independent Mechanisms
por: Sari, Anissa Nofita, et al.
Publicado: (2021)

Why is Mortalin a Potential Therapeutic Target for Cancer?
por: Yoon, A-Rum, et al.
Publicado: (2022)

Inhibition of Bcl-xL prevents pro-death actions of ΔN-Bcl-xL at the mitochondrial inner membrane during glutamate excitotoxicity
por: Park, Han-A, et al.
Publicado: (2017)

Nrz but not zBcl-xL antagonizes Bcl-wav pro-apoptotic activity in zebrafish
por: Prudent, Julien, et al.
Publicado: (2014)

Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancer
por: Alibek, Kenneth, et al.
Publicado: (2014)

Bioinformatic Analysis of the BCL-xL/BCL2L1 Interactome in Patients with Pancreatic Cancer
por: Magouliotis, Dimitrios E., et al.
Publicado: (2022)

Dynamics of Bcl-xL in Water and Membrane: Molecular Simulations
por: Maity, Atanu, et al.
Publicado: (2013)

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin
por: Baranski, Zuzanna, et al.
Publicado: (2015)

Regulation of apoptosis by an intrinsically disordered region of Bcl-xL
por: Follis, Ariele Viacava, et al.
Publicado: (2018)

The Role of Bcl-xL Protein Research in Veterinary Oncology
por: Pawlak, Aleksandra, et al.
Publicado: (2020)

Bcl-xL activity influences outcome of the mitotic arrest
por: Suleimenov, M., et al.
Publicado: (2022)

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
por: Lv, Dongwen, et al.
Publicado: (2021)

Bcl-xL affects the development of functional CD4 Tregs
por: Sharabi, Amir, et al.
Publicado: (2010)

Bcl-xL inhibition - a novel strategy for glioma therapy
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

ΔN-Bcl-xL, a therapeutic target for neuroprotection
por: Park, Han-A, et al.
Publicado: (2017)

Retromer facilitates the localization of Bcl-xL to the mitochondrial outer membrane
por: Farmer, Trey, et al.
Publicado: (2019)

Effects of Cardiolipin on the Conformational Dynamics of Membrane-Anchored Bcl-xL
por: Tyagi, Vivek, et al.
Publicado: (2021)

Functional impact of cancer patient‐associated Bcl‐xL mutations
por: Zhang, Tiantian, et al.
Publicado: (2020)

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
por: Li, Ji-Yu, et al.
Publicado: (2012)

Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
por: Zhang, Yiru, et al.
Publicado: (2018)

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
por: Shang, Enyuan, et al.
Publicado: (2018)

Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
por: Ritter, Violetta, et al.
Publicado: (2021)

Characterization and prognostic significance of mortalin, Bcl-2 and Bax in intrahepatic cholangiocarcinoma
por: Kang, Qiang, et al.
Publicado: (2018)

Relevance of mortalin to cancer cell stemness and cancer therapy
por: Yun, Chae-Ok, et al.
Publicado: (2017)

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
por: Yosef, Reut, et al.
Publicado: (2016)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j0qbpub8a6ie54mt3883d54uii